Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2020 | Nov. 10, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | ThermoGenesis Holdings, Inc. | |
Entity Central Index Key | 0000811212 | |
Trading Symbol | thmo | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 7,796,170 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false | |
Title of 12(b) Security | Common Stock, $.001 par value |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 4,436,000 | $ 3,157,000 |
Restricted cash | 1,000,000 | |
Accounts receivable, net of allowance for doubtful accounts of $220,000 ($226,000 at December 31, 2019) | 1,698,000 | 1,278,000 |
Inventories, net of reserves of $755,000 ($350,000 at December 31, 2019) | 5,876,000 | 3,824,000 |
Prepaid expenses and other current assets | 766,000 | 602,000 |
Total current assets | 12,776,000 | 9,861,000 |
Equipment and leasehold improvements, net | 1,537,000 | 2,028,000 |
Right-of-use operating lease assets, net | 765,000 | 859,000 |
Goodwill | 781,000 | 781,000 |
Intangible assets, net | 1,382,000 | 1,467,000 |
Other assets | 48,000 | 218,000 |
Total assets | 17,289,000 | 15,214,000 |
Current liabilities: | ||
Accounts payable | 1,661,000 | 1,447,000 |
Accrued payroll and related expenses | 513,000 | 288,000 |
Deferred revenue – short-term | 700,000 | 620,000 |
Interest payable – related party | 1,519,000 | 1,869,000 |
Note payable – short-term | 235,000 | |
Other current liabilities | 1,092,000 | 2,461,000 |
Total current liabilities | 5,720,000 | 6,685,000 |
Convertible promissory note – related party, less debt discount of $4,893,000 ($5,195,000 at December 31, 2019) | 5,107,000 | 3,518,000 |
Convertible promissory notes, less debt discount of $588,000 (plus debt premium of $46,000 at December 31, 2019) | 412,000 | 413,000 |
Note payable | 411,000 | 1,000,000 |
Operating lease obligations – long-term | 648,000 | 761,000 |
Deferred revenue – long-term | 1,669,000 | 1,901,000 |
Other noncurrent liabilities | 20,000 | 20,000 |
Total liabilities | 13,987,000 | 14,298,000 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding | ||
Common stock, $0.001 par value; 350,000,000 shares authorized; 6,832,040 issued and outstanding (2,843,601 at December 31, 2019) | 7,000 | 3,000 |
Additional paid in capital | 253,537,000 | 237,313,000 |
Accumulated deficit | (250,434,000) | (236,932,000) |
Accumulated other comprehensive loss | 22,000 | 2,000 |
Total ThermoGenesis Holdings, Inc. stockholders’ equity | 3,132,000 | 386,000 |
Noncontrolling interests | 170,000 | 530,000 |
Total equity | 3,302,000 | 916,000 |
Total liabilities and equity | $ 17,289,000 | $ 15,214,000 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Accounts receivable, allowance for doubtful accounts | $ 220,000 | $ 226,000 |
Inventories, reserves | 755,000 | 350,000 |
Debt discount | $ 588,000 | $ 46,000 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 2,000,000 | 2,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 350,000,000 | 350,000,000 |
Common stock, shares issued (in shares) | 6,832,040 | 2,843,601 |
Common stock, shares outstanding (in shares) | 6,832,040 | 2,843,601 |
Convertible Promissory Note [Member] | ||
Debt discount | $ 4,893,000 | $ 5,195,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Net revenues | $ 2,355,000 | $ 4,058,000 | $ 7,797,000 | $ 11,325,000 |
Cost of revenues | 844,000 | 2,163,000 | 7,426,000 | 6,220,000 |
Gross profit | 1,511,000 | 1,895,000 | 371,000 | 5,105,000 |
Expenses: | ||||
Sales and marketing | 539,000 | 502,000 | 1,424,000 | 1,227,000 |
Research and development | 750,000 | 584,000 | 1,937,000 | 1,758,000 |
General and administrative | 1,305,000 | 1,139,000 | 4,489,000 | 3,617,000 |
Total operating expenses | 2,594,000 | 2,225,000 | 7,850,000 | 6,602,000 |
Loss from operations | (1,083,000) | (330,000) | (7,479,000) | (1,497,000) |
Other income (expenses): | ||||
Interest expense | (1,531,000) | (1,188,000) | (6,377,000) | (3,531,000) |
Loss on equity method investments | (13,000) | |||
Loss on extinguishment of debt | (840,000) | (840,000) | ||
Other income (expense) | 5,000 | (15,000) | 7,000 | (27,000) |
Total other expense | (1,526,000) | (2,043,000) | (6,383,000) | (4,398,000) |
Net loss | (2,609,000) | (2,373,000) | (13,862,000) | (5,895,000) |
Loss attributable to noncontrolling interests | (146,000) | (91,000) | (360,000) | (445,000) |
Net loss attributable to common stockholders | (2,463,000) | (2,282,000) | (13,502,000) | (5,450,000) |
Net loss | (2,609,000) | (2,373,000) | (13,862,000) | (5,895,000) |
Other comprehensive loss: | ||||
Foreign currency translation adjustments gain (loss) | (19,000) | 16,000 | 20,000 | 9,000 |
Comprehensive loss | (2,628,000) | (2,357,000) | (13,842,000) | (5,886,000) |
Comprehensive loss attributable to noncontrolling interests | (146,000) | (91,000) | (360,000) | (445,000) |
Comprehensive loss attributable to common stockholders | $ (2,482,000) | $ (2,266,000) | $ (13,482,000) | $ (5,441,000) |
Per share data: | ||||
Basic and diluted net loss per common share (in dollars per share) | $ (0.37) | $ (0.78) | $ (2.36) | $ (2) |
Weighted average common shares outstanding basic and diluted (in shares) | 6,711,664 | 2,913,198 | 5,728,105 | 2,720,502 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Equity (Unaudited) - USD ($) | Boyalife Investment Fund II, Inc. [Member]Common Stock [Member] | Boyalife Investment Fund II, Inc. [Member]Additional Paid-in Capital [Member] | Boyalife Investment Fund II, Inc. [Member]Retained Earnings [Member] | Boyalife Investment Fund II, Inc. [Member]AOCI Attributable to Parent [Member] | [1] | Boyalife Investment Fund II, Inc. [Member]Noncontrolling Interest [Member] | Boyalife Investment Fund II, Inc. [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | [1] | Noncontrolling Interest [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 2,168,337 | |||||||||||||
Balance at Dec. 31, 2018 | $ 2,000 | $ 235,888,000 | $ (227,435,000) | $ (13,000) | $ (1,711,000) | $ 6,731,000 | ||||||||
Stock-based compensation expense | 81,000 | 81,000 | ||||||||||||
Exercise of pre-funded warrants (in shares) | 50,000 | |||||||||||||
Exercise of pre-funded warrants | 5,000 | 5,000 | ||||||||||||
Discount due to beneficial conversion features | 1,513,000 | 1,513,000 | ||||||||||||
Foreign currency translation gain (loss) | (4,000) | (4,000) | ||||||||||||
Net loss | (1,871,000) | (176,000) | (2,047,000) | |||||||||||
Reorganization of subsidiary and related change in non-controlling interest | (2,843,000) | 2,843,000 | ||||||||||||
Balance (in shares) at Mar. 31, 2019 | 2,218,337 | |||||||||||||
Balance at Mar. 31, 2019 | $ 2,000 | 234,644,000 | (229,306,000) | (17,000) | 956,000 | 6,279,000 | ||||||||
Balance (in shares) at Dec. 31, 2018 | 2,168,337 | |||||||||||||
Balance at Dec. 31, 2018 | $ 2,000 | 235,888,000 | (227,435,000) | (13,000) | (1,711,000) | 6,731,000 | ||||||||
Foreign currency translation gain (loss) | 9,000 | |||||||||||||
Balance (in shares) at Sep. 30, 2019 | 2,704,837 | |||||||||||||
Balance at Sep. 30, 2019 | $ 3,000 | 236,830,000 | (232,885,000) | (4,000) | 687,000 | 4,631,000 | ||||||||
Balance (in shares) at Mar. 31, 2019 | 2,218,337 | |||||||||||||
Balance at Mar. 31, 2019 | $ 2,000 | 234,644,000 | (229,306,000) | (17,000) | 956,000 | 6,279,000 | ||||||||
Stock-based compensation expense | 125,000 | 125,000 | ||||||||||||
Exercise of pre-funded warrants (in shares) | 150,000 | |||||||||||||
Exercise of pre-funded warrants | 18,000 | 18,000 | ||||||||||||
Discount due to beneficial conversion features | 800,000 | 800,000 | ||||||||||||
Issuance of common stock, net | 756,000 | 756,000 | ||||||||||||
Foreign currency translation gain (loss) | (3,000) | (3,000) | ||||||||||||
Net loss | (1,297,000) | (178,000) | (1,475,000) | |||||||||||
Balance (in shares) at Jun. 30, 2019 | 2,368,337 | |||||||||||||
Balance at Jun. 30, 2019 | $ 2,000 | 236,343,000 | (230,603,000) | (20,000) | 778,000 | 6,500,000 | ||||||||
Stock-based compensation expense | 253,000 | 253,000 | ||||||||||||
Exercise of pre-funded warrants (in shares) | 216,500 | |||||||||||||
Exercise of pre-funded warrants | $ 1,000 | 18,000 | 19,000 | |||||||||||
Conversion of note payable to common stock (in shares) | 120,000 | |||||||||||||
Conversion of note payable to common stock | 216,000 | 216,000 | ||||||||||||
Foreign currency translation gain (loss) | 16,000 | 16,000 | ||||||||||||
Net loss | (2,282,000) | (91,000) | (2,373,000) | |||||||||||
Balance (in shares) at Sep. 30, 2019 | 2,704,837 | |||||||||||||
Balance at Sep. 30, 2019 | $ 3,000 | 236,830,000 | (232,885,000) | (4,000) | 687,000 | 4,631,000 | ||||||||
Balance (in shares) at Dec. 31, 2019 | 2,843,601 | |||||||||||||
Balance at Dec. 31, 2019 | $ 3,000 | 237,313,000 | (236,932,000) | 2,000 | 530,000 | 916,000 | ||||||||
Stock-based compensation expense | 67,000 | 67,000 | ||||||||||||
Exercise of pre-funded warrants (in shares) | 100,000 | |||||||||||||
Exercise of pre-funded warrants | 10,000 | 10,000 | ||||||||||||
Exercise of warrants (in shares) | 7,866 | |||||||||||||
Exercise of warrants | 47,000 | 47,000 | ||||||||||||
Discount due to beneficial conversion features | 1,869,000 | 1,869,000 | ||||||||||||
Conversion of note payable to common stock (in shares) | 1,666,670 | 100,000 | ||||||||||||
Conversion of note payable to common stock | $ 2,000 | $ 2,998,000 | $ 3,000,000 | 180,000 | 180,000 | |||||||||
Issuance of common stock, net (in shares) | 1,050,748 | |||||||||||||
Issuance of common stock, net | $ 1,000 | 3,220,000 | 3,221,000 | |||||||||||
Foreign currency translation gain (loss) | 38,000 | 38,000 | ||||||||||||
Net loss | (4,602,000) | (141,000) | (4,743,000) | |||||||||||
Balance (in shares) at Mar. 31, 2020 | 5,768,885 | |||||||||||||
Balance at Mar. 31, 2020 | $ 6,000 | 245,704,000 | (241,534,000) | 40,000 | 389,000 | 4,605,000 | ||||||||
Balance (in shares) at Dec. 31, 2019 | 2,843,601 | |||||||||||||
Balance at Dec. 31, 2019 | $ 3,000 | 237,313,000 | (236,932,000) | 2,000 | 530,000 | 916,000 | ||||||||
Foreign currency translation gain (loss) | 20,000 | |||||||||||||
Balance (in shares) at Sep. 30, 2020 | 6,832,040 | |||||||||||||
Balance at Sep. 30, 2020 | $ 7,000 | 253,537,000 | (250,434,000) | 22,000 | 170,000 | 3,302,000 | ||||||||
Balance (in shares) at Mar. 31, 2020 | 5,768,885 | |||||||||||||
Balance at Mar. 31, 2020 | $ 6,000 | 245,704,000 | (241,534,000) | 40,000 | 389,000 | 4,605,000 | ||||||||
Stock-based compensation expense | 314,000 | 314,000 | ||||||||||||
Exercise of pre-funded warrants (in shares) | 224,445 | |||||||||||||
Exercise of pre-funded warrants | 22,000 | 22,000 | ||||||||||||
Exercise of warrants (in shares) | 267,271 | |||||||||||||
Exercise of warrants | 1,604,000 | 1,604,000 | ||||||||||||
Discount due to beneficial conversion features | 3,112,000 | 3,112,000 | ||||||||||||
Conversion of note payable to common stock (in shares) | 104,445 | |||||||||||||
Conversion of note payable to common stock | $ 1,000 | 188,000 | 189,000 | |||||||||||
Issuance of common stock, net (in shares) | 344,419 | |||||||||||||
Issuance of common stock, net | 1,993,000 | 1,993,000 | ||||||||||||
Foreign currency translation gain (loss) | 1,000 | 1,000 | ||||||||||||
Net loss | (6,437,000) | (73,000) | (6,510,000) | |||||||||||
Balance (in shares) at Jun. 30, 2020 | 6,709,465 | |||||||||||||
Balance at Jun. 30, 2020 | $ 7,000 | 252,937,000 | (247,971,000) | 41,000 | 316,000 | 5,330,000 | ||||||||
Stock-based compensation expense | 234,000 | 234,000 | ||||||||||||
Issuance of common stock, net (in shares) | 122,575 | |||||||||||||
Issuance of common stock, net | 366,000 | 366,000 | ||||||||||||
Foreign currency translation gain (loss) | (19,000) | (19,000) | ||||||||||||
Net loss | (2,463,000) | (146,000) | (2,609,000) | |||||||||||
Balance (in shares) at Sep. 30, 2020 | 6,832,040 | |||||||||||||
Balance at Sep. 30, 2020 | $ 7,000 | $ 253,537,000 | $ (250,434,000) | $ 22,000 | $ 170,000 | $ 3,302,000 | ||||||||
[1] | Accumulated other comprehensive loss. |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | |
Cash flows from operating activities: | |||||
Net loss | $ (2,609,000) | $ (2,373,000) | $ (13,862,000) | $ (5,895,000) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Depreciation and amortization | 569,000 | 604,000 | |||
Stock based compensation expense | 615,000 | 459,000 | |||
Amortization of debt discount/premium, net | 2,165,000 | 1,799,000 | |||
Amortization of accelerated debt discount due to conversion | 2,486,000 | ||||
Reserve for excess and slow-moving inventories | 4,036,000 | 141,000 | |||
Reserve for bad debt expense | (6,000) | (53,000) | |||
Change in fair value derivative | 2,000 | ||||
Loss on disposal of equipment | 118,000 | 20,000 | |||
Loss on extinguishment of debt | 840,000 | 840,000 | |||
Net change in operating assets and liabilities: | |||||
Accounts receivable | (414,000) | (2,908,000) | |||
Inventories | (6,086,000) | 980,000 | |||
Prepaid expenses and other assets | 6,000 | (227,000) | |||
Accounts payable | 223,000 | (542,000) | |||
Interest payable - related party | (350,000) | (116,000) | |||
Accrued payroll and related expenses | 225,000 | (298,000) | |||
Deferred revenue – short-term | 80,000 | 354,000 | |||
Other current liabilities | (1,326,000) | (145,000) | |||
Long-term deferred revenue and other noncurrent liabilities | (338,000) | 1,467,000 | |||
Net cash used in operating activities | (11,859,000) | (3,518,000) | |||
Cash flows from investing activities: | |||||
Capital expenditures | (23,000) | (178,000) | |||
Net cash used in investing activities | (23,000) | (178,000) | |||
Cash flows from financing activities: | |||||
Proceeds from convertible promissory note-related party | 4,287,000 | 1,513,000 | |||
Payments on financing lease obligations | (32,000) | (15,000) | |||
Proceeds from issuance of common stock, net of expenses | 5,580,000 | 756,000 | |||
Proceeds from exercise of options, warrants and pre-funded warrants | 1,683,000 | 42,000 | |||
Proceeds from long-term debt | 1,800,000 | ||||
Proceeds from note payable | 646,000 | ||||
Net cash provided by financing activities | 12,164,000 | 4,096,000 | |||
Effects of foreign currency rate changes on cash and cash equivalents | (3,000) | ||||
Net increase (decrease) in cash, cash equivalents and restricted cash | 279,000 | 400,000 | |||
Cash, cash equivalents and restricted cash at beginning of period | 4,157,000 | 3,400,000 | $ 3,400,000 | ||
Cash, cash equivalents and restricted cash at end of period | $ 4,436,000 | $ 3,800,000 | 4,436,000 | 3,800,000 | $ 4,157,000 |
Supplemental disclosures of cash flow information: | |||||
Cash paid for interest | 2,094,000 | 1,613,000 | |||
Supplemental non-cash financing and investing information: | |||||
Recording of beneficial conversion feature on debt | 4,981,000 | 2,313,000 | |||
Right-to-use asset acquired under operating lease | 966,000 | ||||
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note | 1,473,000 | ||||
Transfer of equipment to inventories | 33,000 | ||||
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member] | |||||
Supplemental non-cash financing and investing information: | |||||
Promissory note converted to common stock | 3,000,000 | ||||
Conversion of January 2019 Amended Notes to Common Stock [Member] | |||||
Supplemental non-cash financing and investing information: | |||||
Promissory note converted to common stock | $ 369,000 | $ 216,000 |
Note 1 - Description of Busines
Note 1 - Description of Business, Basis of Presentation and Going Concern | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1. D ESCRIPTION OF B USINESS , B ASIS OF P RESENTATION AND GOING CONCERN Organization and Basis of Presentation ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”) develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 The Company previously had two 2019, no no no two ® ® ® Clinical Bio-Banking Applications: ● AXP ® ● BioArchive ® Point-of-Care Applications: ● PXP ® Large Scale Cell Processing and Biomanufacturing: ● X ® X ® X ® X ® X ● CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. CAR-TXpress Bio, Inc. (“CARTXpress Bio”) is owned and developed through a subsidiary in which we own 80% COVID- 19 ● Antibody Test – The ThermoGenesis SARS-CoV- 2 2 On January 1, 2019, July 2017 20% third 20% 80% 100% In the reorganization, the Company reacquired the non-controlling interest shares in ThermoGenesis Corp., which had an accumulated deficit of $1,711,000, 20% $1,100,000. $2,843,000 On November 26, 2019 80% 20% 18.79% ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics. Reverse Stock Split On June 4, 2019, one 1 ten 10 350,000,000 not Going Concern The Company has a Revolving Credit Agreement (“Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note 3 $10,000,000 September 30, 2020, $10,000,000. On April 21, 2020, $646,000 $235,000 $411,000. two 1.00% first six may may At September 30, 2020, $4,436,000 $7,056,000. September 30, 2020 $250,434,000. one may may The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company's ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp's majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. Non-controlling Interests The 20% not 80% Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. three nine September 30, 2020 not may December 31, 2020. 10 December 31, 2019. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Recently Issued Accounting Standards In August 2020, 2020 06 “Debt-Debt with Conversion and Other Options ( “ Subtopic 470 20 ” ) and Derivatives and Hedging—Contracts in Entity's Own Equity ( “ Subtopic 815 40 ” ): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,” 1 2 3 may January 1, 2022 January 1, 2021. In December 2019, 2019 12 Income Taxes ( “ Topic 740 ” ): Simplifying the Accounting of Income Taxes , 2019 12 740 December 15, 2020, In June 2016, ASU 2016 13, “ Financial Instruments - Credit Losses ( “ Topic 326 ” ). ” 2016 13 December 15, 2022, not Recently Adopted Accounting Standards In August 2018, 2018 13, Fair Value Measurement (“Topic 820” not Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues by product line: Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 221,000 -- -- 221,000 CAR-TXpress 875,000 10,000 33,000 918,000 Other -- -- 19,000 19,000 Total $ 3,594,000 $ 412,000 $ 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 764,000 -- -- 764,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other 5,000 11,000 40,000 56,000 Total $ 9,958,000 $ 1,294,000 $ 73,000 $ 11,325,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2020 $115,000 $547,000, $620,000 $700,000 $1,901,000 $1,669,000 nine September 30, 2020, Exclusivity Fee On August 30, 2019, five two X ® $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven three nine September 30, 2020, $71,000 $214,000, $2,000,000 $1,690,000 $286,000 $1,404,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 310,000 $ 958,000 $ 561,000 $ 298,000 $ 38,000 $ 2,165,000 Clinical revenue 3,000 13,000 13,000 13,000 175,000 217,000 Exclusivity fee 71,000 286,000 286,000 286,000 761,000 1,690,000 Total $ 384,000 $ 1,257,000 $ 860,000 $ 597,000 $ 974,000 $ 4,072,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs which are supported by little or no The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level 3 not 3 Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no September 30, 2020, none September 30: 2020 2019 Common stock equivalents of convertible promissory note and accrued interest 6,988,334 6,013,667 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,006,190 1,300,091 Stock options 892,149 296,029 Total 8,996,967 7,720,081 ___________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not |
Note 3 - Related Party Transact
Note 3 - Related Party Transactions | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 3. Related Party Transactions Health B anks Biotech (USA) Inc. On November 26, 2019 80% 20% 18.79% first 115% 2018 no $1,000,000 Between November 26, 2019 September 30, 2020, $3,700,000 643,750 $5.00 $16.00 6.05% no 75.16% 18.79% 6.05% The Company initially determined that ImmuneCyte would be considered a variable interest entity, as a result of the significant influence the Company has over operations and its' lack of sufficient equity at inception. After the additional investment of $3,700,000, no $28,000, The Company entered into a supply agreement with ImmuneCyte with an effective date of April 22, 2020. 19 one thirty 30 $3,600,000 nine September 30, 2020. August 2020, $800,000 September 30, 2020. nine September 30, 2020, September 30, 2020 $2,800,000. 19 August 2020 For the three nine September 30, 2020, $0 $13,000, September 30, 2020, $0. three nine September 30, 2020, $1,313,000 $1,422,000, September 30, 2020, $2,120,000 $296,000. Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( February 2020, $1,869,000 $3,000,000 1,666,670 two $2,486,000 April 28, 2020, $2,418,000 $10,000,000 $580,000. 2 19 September 30, 2020, $10,000,000. The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender's obligation to make advances under the Loan is subject to the Company's representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended in April 2018. $16.10 two 2018, $1.80. It was concluded that the conversion option of the draw down in February 2020 $1,869,000 March 31, 2020. April 2020 $2,418,000 June 30, 2020. $828,000 $2,103,000 three nine September 30, 2020, $471,000 $1,398,000 three nine September 30, 2019, September 30, 2020, $1,519,000 $1,869,000 December 31, 2019 Distributor Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two During the three nine September 30, 2020, no three nine September 30, 2019, $214,000 $794,000, |
Note 4 - Convertible Promissory
Note 4 - Convertible Promissory Note | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 4. CONVERTIBLE PROMISSORY NOTE On January 29, 2019, $800,000 “January 2019 six $1.80 90% $0.50 The January 2019 twenty-four 24% January 2019 eighteen 18 January 2019 January 2019 may On the date that is six January 2019 January 2019 January 2019 may January 2019 January 2019 4.99% 9.99% $800,000, May 30, 2019. On July 23, 2019, No. 1 January 2019 January 2019 July 29, 2020 July 31, 2022. January 2019 January 2019 January 2019 10% January 2019 $840,000 December 31, 2019. $1,473,000 $556,000 December 31, 2019. $77,000 January 2019 December 31, 2019. During the nine September 30, 2020, nine September 30, 2020, $369,000 204,445 $46,000 nine September 30, 2020. On July 23, 2019, $1,000,000 “July 2019 $1.80 90% $0.50 July 2019 twenty-four 24% July 2019 three July 31, 2022. The July 2019 may six July 2019 may July 2019 July 2019 $694,000, June 4, 2020. July 2019 three nine September 30, 2020, $27,000 $107,000, |
Note 5 - Leases
Note 5 - Leases | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 5 . LEASES The Company leases the Rancho Cordova, California and Gurgaon, India facilities pursuant to operating leases. The Rancho Cordova lease expires in May 2024. September 2023; three Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company's operating leases: September 30, 2020 Right-of-use operating lease assets, net $ 765,000 Current lease liability 147,000 Non-current lease liability 648,000 Weighted average remaining lease term 3.7 Discount rate 22 % Maturities of lease liabilities by year for our operating leases are as follows: 2020 (remaining) $ 76,000 2021 310,000 2022 319,000 2023 328,000 2024 139,000 Thereafter -- Total lease payments $ 1,172,000 Less: imputed interest (377,000 ) Present value of operating lease liabilities $ 795,000 Statement of Cash Flows In January 2019, $966,000 $225,000 nine September 30, 2020 Operating Lease Costs Operating lease costs were $135,000 $343,000 three nine September 30, 2020, 30 Finance Leases Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases are not not three nine September 30, 2020. |
Note 6 - Commitments and Contin
Note 6 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 6 . COMMITMENTS AND CONTINGENCIES Financial Covenants Effective March 16, 2020, #1 May 15, 2017 $2.0 $1.0 one On July 13, 2020, #2 July 13, 2020 ( one $1,000,000 The Company was in compliance with this financial covenant as of September 30, 2020. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the nine September 30, 2020 Balance at December 31, 2019 $ 277,000 Warranties issued during the period 62,000 Settlements made during the period (171,000 ) Changes in liability for pre-existing warranties during the period (20,000 ) Balance at September 30, 2020 $ 148,000 Contingen cies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 February 2020 $1,000,000. $1,400,000 December 31, 2019. $1,000,000 $400,000 $1,000,000 no April 2020, May 1, 2020 $480,000, $369,000 $111,000 not $1,000,000 In the normal course of operations, the Company may September 30, 2020, may not |
Note 7 - Stockholders' Equity
Note 7 - Stockholders' Equity | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 7 . STOCKHOLDERS' EQUITY Common Stock On March 25, 2020, three 1,000,002 $3.50 $3.5 $393,000 3 No. 333 235509 December 13, 2019 January 3, 2020, March 27, 2020. March 27, 2020. 30 twelve 12 On December 13, 2019, may $4.4 May 19, 2020 $15,280,313 3 No. 333 235509 may 415 1933, may not August 9, 2022. 3% September 30, 2020, 517,740 $2,785,000 $5.38 $2,473,000 $312,000. Subsequent to September 30, 2020, 964,130 $2,771,000 $2.87 $2,683,000 $88,000. Stock Based Compensation The Company recorded stock-based compensation of $234,000 $615,000 three nine September 30, 2020, $253,000 $459,000 three nine September 30, 2019, Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of revenues $ 3,000 $ 1,000 $ 5,000 $ 2,000 Sales and marketing 65,000 110,000 106,000 166,000 Research and development 36,000 38,000 72,000 75,000 General and administrative 130,000 104,000 432,000 216,000 Total $ 234,000 $ 253,000 $ 615,000 $ 459,000 The following is a summary of option activity for the Company's stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2019 291,807 $ 13.96 Granted 615,500 $ 5.92 Forfeited (15,158 ) $ 5.13 Outstanding at September 30, 2020 892,149 $ 8.57 8.997 $ -- Vested and expected to vest at September 30, 2020 565,836 $ 9.91 8.736 $ -- Exercisable at September 30, 2020 184,137 $ 17.05 7.665 $ -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock. There were no nine September 30, 2020. Warrants A summary of warrant activity for the nine September 30, 2020 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2019 1,716,066 $ 25.23 Warrants expired -- -- Warrants exercised (599,582 ) $ 2.81 Outstanding at September 30, 2020 1,116,484 $ 37.27 Exercisable at September 30, 2020 1,046,631 $ 34.42 |
Note 8 - Major Customers and Ac
Note 8 - Major Customers and Accounts Receivable | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | 8 . MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE The Company had certain customers whose revenue individually represented 10% 10% For the three September 30, 2020 2019, one 22% 27% second 20% 13% third 10% 2% nine September 30, 2020 2019, one 28% 29% second 12% 13% third 12% 0% At September 30, 2020, two 59% December 31, 2019, three 53% |
Note 9 - Subsequent Events
Note 9 - Subsequent Events | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 9 . S UBSEQUENT EVENTS The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued Accounting Standards In August 2020, 2020 06 “Debt-Debt with Conversion and Other Options ( “ Subtopic 470 20 ” ) and Derivatives and Hedging—Contracts in Entity's Own Equity ( “ Subtopic 815 40 ” ): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,” 1 2 3 may January 1, 2022 January 1, 2021. In December 2019, 2019 12 Income Taxes ( “ Topic 740 ” ): Simplifying the Accounting of Income Taxes , 2019 12 740 December 15, 2020, In June 2016, ASU 2016 13, “ Financial Instruments - Credit Losses ( “ Topic 326 ” ). ” 2016 13 December 15, 2022, not Recently Adopted Accounting Standards In August 2018, 2018 13, Fair Value Measurement (“Topic 820” not |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues by product line: Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 221,000 -- -- 221,000 CAR-TXpress 875,000 10,000 33,000 918,000 Other -- -- 19,000 19,000 Total $ 3,594,000 $ 412,000 $ 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 764,000 -- -- 764,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other 5,000 11,000 40,000 56,000 Total $ 9,958,000 $ 1,294,000 $ 73,000 $ 11,325,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2020 $115,000 $547,000, $620,000 $700,000 $1,901,000 $1,669,000 nine September 30, 2020, Exclusivity Fee On August 30, 2019, five two X ® $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven three nine September 30, 2020, $71,000 $214,000, $2,000,000 $1,690,000 $286,000 $1,404,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 310,000 $ 958,000 $ 561,000 $ 298,000 $ 38,000 $ 2,165,000 Clinical revenue 3,000 13,000 13,000 13,000 175,000 217,000 Exclusivity fee 71,000 286,000 286,000 286,000 761,000 1,690,000 Total $ 384,000 $ 1,257,000 $ 860,000 $ 597,000 $ 974,000 $ 4,072,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs which are supported by little or no The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level 3 not 3 |
Earnings Per Share, Policy [Policy Text Block] | Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no September 30, 2020, none September 30: 2020 2019 Common stock equivalents of convertible promissory note and accrued interest 6,988,334 6,013,667 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,006,190 1,300,091 Stock options 892,149 296,029 Total 8,996,967 7,720,081 ___________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 221,000 -- -- 221,000 CAR-TXpress 875,000 10,000 33,000 918,000 Other -- -- 19,000 19,000 Total $ 3,594,000 $ 412,000 $ 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 764,000 -- -- 764,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other 5,000 11,000 40,000 56,000 Total $ 9,958,000 $ 1,294,000 $ 73,000 $ 11,325,000 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] | Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 310,000 $ 958,000 $ 561,000 $ 298,000 $ 38,000 $ 2,165,000 Clinical revenue 3,000 13,000 13,000 13,000 175,000 217,000 Exclusivity fee 71,000 286,000 286,000 286,000 761,000 1,690,000 Total $ 384,000 $ 1,257,000 $ 860,000 $ 597,000 $ 974,000 $ 4,072,000 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | 2020 2019 Common stock equivalents of convertible promissory note and accrued interest 6,988,334 6,013,667 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,006,190 1,300,091 Stock options 892,149 296,029 Total 8,996,967 7,720,081 |
Note 5 - Leases (Tables)
Note 5 - Leases (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Lease, Cost [Table Text Block] | September 30, 2020 Right-of-use operating lease assets, net $ 765,000 Current lease liability 147,000 Non-current lease liability 648,000 Weighted average remaining lease term 3.7 Discount rate 22 % |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | 2020 (remaining) $ 76,000 2021 310,000 2022 319,000 2023 328,000 2024 139,000 Thereafter -- Total lease payments $ 1,172,000 Less: imputed interest (377,000 ) Present value of operating lease liabilities $ 795,000 |
Note 6 - Commitments and Cont_2
Note 6 - Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Product Warranty Liability [Table Text Block] | Balance at December 31, 2019 $ 277,000 Warranties issued during the period 62,000 Settlements made during the period (171,000 ) Changes in liability for pre-existing warranties during the period (20,000 ) Balance at September 30, 2020 $ 148,000 |
Note 7 - Stockholders' Equity (
Note 7 - Stockholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of revenues $ 3,000 $ 1,000 $ 5,000 $ 2,000 Sales and marketing 65,000 110,000 106,000 166,000 Research and development 36,000 38,000 72,000 75,000 General and administrative 130,000 104,000 432,000 216,000 Total $ 234,000 $ 253,000 $ 615,000 $ 459,000 |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2019 291,807 $ 13.96 Granted 615,500 $ 5.92 Forfeited (15,158 ) $ 5.13 Outstanding at September 30, 2020 892,149 $ 8.57 8.997 $ -- Vested and expected to vest at September 30, 2020 565,836 $ 9.91 8.736 $ -- Exercisable at September 30, 2020 184,137 $ 17.05 7.665 $ -- |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2019 1,716,066 $ 25.23 Warrants expired -- -- Warrants exercised (599,582 ) $ 2.81 Outstanding at September 30, 2020 1,116,484 $ 37.27 Exercisable at September 30, 2020 1,046,631 $ 34.42 |
Note 1 - Description of Busin_2
Note 1 - Description of Business, Basis of Presentation and Going Concern (Details Textual) | Apr. 21, 2020USD ($) | Jun. 04, 2019shares | Jan. 01, 2019USD ($) | Mar. 31, 2019USD ($) | Sep. 30, 2020USD ($)shares | Jun. 30, 2020 | Apr. 28, 2020USD ($) | Dec. 31, 2019USD ($)shares | Nov. 26, 2019USD ($) | Mar. 31, 2017USD ($) |
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance | $ 170,000 | $ 530,000 | ||||||||
Reorganization of Subsidiary and Related Change in Non-controlling Interest | ||||||||||
Common Stock, Shares Authorized (in shares) | shares | 350,000,000 | 350,000,000 | 350,000,000 | |||||||
Notes Payable, Current, Total | $ 235,000 | |||||||||
Notes Payable, Noncurrent, Total | 411,000 | 1,000,000 | ||||||||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | 4,436,000 | 3,157,000 | ||||||||
Working Capital | 7,056,000 | |||||||||
Retained Earnings (Accumulated Deficit), Ending Balance | (250,434,000) | $ (236,932,000) | ||||||||
Paycheck Protection Program CARES Act [Member] | ||||||||||
Proceeds from Issuance of Long-term Debt, Total | $ 646,000 | |||||||||
Notes Payable, Current, Total | 235,000 | |||||||||
Notes Payable, Noncurrent, Total | 411,000 | |||||||||
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member] | ||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 10,000,000 | $ 10,000,000 | ||||||||
Long-term Line of Credit, Total | $ 10,000,000 | $ 10,000,000 | ||||||||
Reverse Stock Split [Member] | ||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 10 | |||||||||
ImmuneCyte [Member] | ||||||||||
Equity Method Investment, Ownership Percentage | 18.79% | 20.00% | ||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 1,000,000 | |||||||||
ImmuneCyte [Member] | HealthBanks Biotech [Member] | ||||||||||
Equity Method Investment, Ownership Percentage | 75.16% | 80.00% | ||||||||
Noncontrolling Interest [Member] | ||||||||||
Reorganization of Subsidiary and Related Change in Non-controlling Interest | $ 2,843,000 | $ 2,843,000 | ||||||||
CAR-TXpress [Member] | ||||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 80.00% | 80.00% | 80.00% | |||||||
Minority Interest Acquired Through Exchange | 20.00% | |||||||||
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance | $ 1,100,000 | |||||||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 20.00% | |||||||||
ThermoGenesis [Member] | ||||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 100.00% | |||||||||
Ownership in Subsidiary Exchanged | 20.00% | |||||||||
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance | $ (1,711,000) |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) | Aug. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2020 | Dec. 31, 2019 |
Contract with Customer, Liability, Revenue Recognized | $ 115,000 | $ 547,000 | ||
Deferred Revenue, Current, Total | 700,000 | 700,000 | $ 620,000 | |
Deferred Revenue, Noncurrent, Total | 1,669,000 | 1,669,000 | $ 1,901,000 | |
Exclusivity Fee [Member] | ||||
Deferred Revenue, Current, Total | 286,000 | 286,000 | ||
Deferred Revenue, Noncurrent, Total | 1,404,000 | 1,404,000 | ||
Deferred Revenue, Total | 1,690,000 | 1,690,000 | ||
Exclusivity Fee [Member] | ||||
Contract with Customer, Liability, Revenue Recognized | $ 71,000 | $ 214,000 | ||
Exclusivity Fee Recognize Period (Year) | 7 years | |||
Supply Agreement [Member] | ||||
Supply Agreement, Term (Year) | 5 years | |||
Supply Agreement, Renewal Term (Year) | 2 years | 2 years | ||
Contract with Customer, Liability, Total | $ 2,000,000 | |||
Proceeds from Customers | $ 2,000,000 |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Net revenues | $ 2,355,000 | $ 4,058,000 | $ 7,797,000 | $ 11,325,000 |
Device [Member] | AXP [Member] | ||||
Net revenues | 1,169,000 | 2,306,000 | 4,112,000 | 6,710,000 |
Device [Member] | BioArchive [Member] | ||||
Net revenues | 619,000 | 594,000 | 1,575,000 | 2,391,000 |
Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 425,000 | 918,000 | 1,296,000 | 1,404,000 |
Device [Member] | Manual Disposables [Member] | ||||
Net revenues | 100,000 | 221,000 | 499,000 | 764,000 |
Device [Member] | Other Subsegments [Member] | ||||
Net revenues | 42,000 | 19,000 | 315,000 | 56,000 |
Device Revenue [Member] | ||||
Net revenues | 1,932,000 | 3,594,000 | 6,494,000 | 9,958,000 |
Device Revenue [Member] | Device [Member] | AXP [Member] | ||||
Net revenues | 1,137,000 | 2,255,000 | 4,009,000 | 6,550,000 |
Device Revenue [Member] | Device [Member] | BioArchive [Member] | ||||
Net revenues | 337,000 | 243,000 | 675,000 | 1,274,000 |
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 332,000 | 875,000 | 1,035,000 | 1,365,000 |
Device Revenue [Member] | Device [Member] | Manual Disposables [Member] | ||||
Net revenues | 100,000 | 221,000 | 499,000 | 764,000 |
Device Revenue [Member] | Device [Member] | Other Subsegments [Member] | ||||
Net revenues | 26,000 | 276,000 | 5,000 | |
Service [Member] | ||||
Net revenues | 336,000 | 412,000 | 1,050,000 | 1,294,000 |
Service [Member] | Device [Member] | AXP [Member] | ||||
Net revenues | 32,000 | 51,000 | 103,000 | 160,000 |
Service [Member] | Device [Member] | BioArchive [Member] | ||||
Net revenues | 282,000 | 351,000 | 900,000 | 1,117,000 |
Service [Member] | Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 22,000 | 10,000 | 47,000 | 6,000 |
Service [Member] | Device [Member] | Manual Disposables [Member] | ||||
Net revenues | ||||
Service [Member] | Device [Member] | Other Subsegments [Member] | ||||
Net revenues | 11,000 | |||
Other [Member] | ||||
Net revenues | 87,000 | 52,000 | 253,000 | 73,000 |
Other [Member] | Device [Member] | AXP [Member] | ||||
Net revenues | ||||
Other [Member] | Device [Member] | BioArchive [Member] | ||||
Net revenues | ||||
Other [Member] | Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 71,000 | 33,000 | 214,000 | 33,000 |
Other [Member] | Device [Member] | Manual Disposables [Member] | ||||
Net revenues | ||||
Other [Member] | Device [Member] | Other Subsegments [Member] | ||||
Net revenues | $ 16,000 | $ 19,000 | $ 39,000 | $ 40,000 |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details) | Sep. 30, 2020USD ($) |
Revenue, Remaining Performance Obligation, Amount | $ 4,072,000 |
Service [Member] | |
Revenue, Remaining Performance Obligation, Amount | 2,165,000 |
Clinical Revenue [Member] | |
Revenue, Remaining Performance Obligation, Amount | 217,000 |
Exclusivity Fee [Member] | |
Revenue, Remaining Performance Obligation, Amount | $ 1,690,000 |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details) | Sep. 30, 2020USD ($) |
Revenue, Remaining Performance Obligation, Amount | $ 4,072,000 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 91 days |
Revenue, Remaining Performance Obligation, Amount | $ 384,000 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 1,257,000 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 860,000 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 597,000 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 974,000 |
Service [Member] | |
Revenue, Remaining Performance Obligation, Amount | $ 2,165,000 |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 91 days |
Revenue, Remaining Performance Obligation, Amount | $ 310,000 |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 958,000 |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 561,000 |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 298,000 |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 38,000 |
Clinical Revenue [Member] | |
Revenue, Remaining Performance Obligation, Amount | $ 217,000 |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 91 days |
Revenue, Remaining Performance Obligation, Amount | $ 3,000 |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 13,000 |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 13,000 |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 13,000 |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 175,000 |
Exclusivity Fee [Member] | |
Revenue, Remaining Performance Obligation, Amount | $ 1,690,000 |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 91 days |
Revenue, Remaining Performance Obligation, Amount | $ 71,000 |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 286,000 |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 286,000 |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 286,000 |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 761,000 |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | ||
Anti-dilutive securities (in shares) | 8,996,967 | 7,720,081 | |
Convertible Debt Securities [Member] | |||
Anti-dilutive securities (in shares) | 6,988,334 | 6,013,667 | |
Vested Series A Warrants [Member] | |||
Anti-dilutive securities (in shares) | 40,441 | 40,441 | |
Unvested Series A Warrants [Member] | |||
Anti-dilutive securities (in shares) | [1] | 69,853 | 69,853 |
Warrant, Other [Member] | |||
Anti-dilutive securities (in shares) | 1,006,190 | 1,300,091 | |
Share-based Payment Arrangement, Option [Member] | |||
Anti-dilutive securities (in shares) | 892,149 | 296,029 | |
[1] | The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021. |
Note 3 - Related Party Transa_2
Note 3 - Related Party Transactions (Details Textual) - USD ($) | Apr. 28, 2020 | Feb. 29, 2020 | Aug. 21, 2017 | Feb. 29, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Dec. 31, 2019 | Nov. 26, 2019 | Dec. 31, 2018 | Apr. 16, 2018 | Mar. 31, 2017 |
Income (Loss) from Equity Method Investments, Total | $ (13,000) | |||||||||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total | (2,609,000) | (2,373,000) | (13,862,000) | (5,895,000) | ||||||||||
Assets, Current, Total | 12,776,000 | 12,776,000 | $ 12,776,000 | $ 9,861,000 | ||||||||||
Liabilities, Current, Total | 5,720,000 | 5,720,000 | 5,720,000 | 6,685,000 | ||||||||||
Amortization of Accelerated Debt Discount Due to Conversion | 2,486,000 | |||||||||||||
Amortization of Debt Discount (Premium) | 2,165,000 | 1,799,000 | ||||||||||||
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member] | ||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,000,000 | |||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 1,666,670 | |||||||||||||
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member] | ||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 1.80 | $ 16.10 | ||||||||||||
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member] | ||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 10,000,000 | 10,000,000 | 10,000,000 | $ 10,000,000 | ||||||||||
Proceeds from Long-term Lines of Credit | $ 2,418,000 | $ 1,869,000 | ||||||||||||
Amortization of Accelerated Debt Discount Due to Conversion | $ 2,486,000 | |||||||||||||
Long-term Line of Credit, Total | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | ||||||||||
Interest Payable | $ 580,000 | $ 1,519,000 | $ 1,519,000 | $ 1,519,000 | $ 1,869,000 | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 22.00% | 22.00% | 22.00% | |||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 1,869,000 | |||||||||||||
Amortization of Debt Discount (Premium) | $ 828,000 | 471,000 | $ 2,103,000 | 1,398,000 | ||||||||||
Boyalife W.S.N. [Member] | ||||||||||||||
Distributor Agreement Term (Year) | 3 years | |||||||||||||
Distributor Agreement, Renewal Term (Year) | 2 years | |||||||||||||
Revenue from Related Parties | 0 | $ 214,000 | 0 | $ 794,000 | ||||||||||
COVID-19 Testing Kits [Member] | ||||||||||||||
Inventory Write-down | 2,800,000 | |||||||||||||
COVID-19 Testing Kits [Member] | ImmuneCyte [Member] | ||||||||||||||
Related Party Transaction, Purchases from Related Party | $ 3,600,000 | |||||||||||||
Refund from Related Party Purchases | $ 800,000 | |||||||||||||
ImmuneCyte [Member] | ||||||||||||||
Proceeds from Issuance of Common Stock | $ 3,700,000 | |||||||||||||
ImmuneCyte [Member] | Common Class A [Member] | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 643,750 | |||||||||||||
ImmuneCyte [Member] | Common Class A [Member] | Minimum [Member] | ||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 5 | $ 5 | $ 5 | |||||||||||
ImmuneCyte [Member] | Common Class A [Member] | Maximum [Member] | ||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 16 | $ 16 | $ 16 | |||||||||||
ImmuneCyte [Member] | ||||||||||||||
Equity Method Investment, Ownership Percentage | 18.79% | 18.79% | 18.79% | 20.00% | ||||||||||
Joint Venture Purchase, Percent of Company's Cost | 115.00% | |||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 1,000,000 | |||||||||||||
Equity Method Investment, Aggregate Cost | $ 0 | $ 0 | $ 0 | $ 28,000 | ||||||||||
Income (Loss) from Equity Method Investments, Total | 0 | 13,000 | ||||||||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total | 1,313,000 | 1,422,000 | ||||||||||||
Assets, Current, Total | 2,120,000 | 2,120,000 | 2,120,000 | |||||||||||
Liabilities, Current, Total | $ 296,000 | $ 296,000 | $ 296,000 | |||||||||||
ImmuneCyte [Member] | HealthBanks Biotech [Member] | ||||||||||||||
Equity Method Investment, Ownership Percentage | 75.16% | 75.16% | 75.16% | 80.00% | ||||||||||
ImmuneCyte [Member] | Private Institution [Member] | ||||||||||||||
Equity Method Investment, Ownership Percentage | 6.05% | 6.05% | 6.05% |
Note 4 - Convertible Promisso_2
Note 4 - Convertible Promissory Note (Details Textual) - USD ($) | Jun. 04, 2020 | Jul. 23, 2019 | Jan. 29, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | May 30, 2019 |
Gain (Loss) on Extinguishment of Debt, Total | $ (840,000) | $ (840,000) | |||||||
Amortization of Debt Discount (Premium) | 2,165,000 | $ 1,799,000 | |||||||
Conversion of Convertible Promissory Note to Common Stock [Member] | |||||||||
Debt Conversion, Converted Instrument, Amount | $ 369,000 | ||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 204,445 | ||||||||
Interest Income (Expense), Nonoperating, Net | $ 46,000 | ||||||||
Convertible Debt [Member] | Notes [Member] | |||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 90.00% | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 24.00% | ||||||||
Debt Instrument, Term (Month) | 1 year 180 days | ||||||||
Debt Instrument, Convertible, First Customary Conversion Blockers | 4.99% | ||||||||
Debt Instrument, Convertible, Second customary conversion blockers | 9.99% | ||||||||
Debt Instrument, Unamortized Discount, Total | $ 800,000 | ||||||||
Convertible Debt [Member] | Notes [Member] | Maximum [Member] | |||||||||
Debt Instrument, Face Amount | $ 800,000 | ||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 1.80 | ||||||||
Convertible Debt [Member] | Notes [Member] | Minimum [Member] | |||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.50 | ||||||||
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | |||||||||
Debt Instrument, Unamortized Discount, Total | $ 556,000 | ||||||||
Gain (Loss) on Extinguishment of Debt, Total | 840,000 | ||||||||
Long-term Debt, Fair Value | $ 1,473,000 | ||||||||
Amortization of Debt Discount (Premium) | $ 77,000 | ||||||||
Convertible Debt [Member] | The July 2019 Note [Member] | |||||||||
Debt Instrument, Face Amount | $ 1,000,000 | ||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 90.00% | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 24.00% | ||||||||
Amortization of Debt Discount (Premium) | $ 27,000 | $ 107,000 | |||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 694,000 | ||||||||
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member] | |||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 1.80 | ||||||||
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member] | |||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.50 |
Note 5 - Leases (Details Textua
Note 5 - Leases (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2020 | Dec. 31, 2019 | Jan. 01, 2019 | |
Operating Lease, Right-of-Use Asset | $ 765,000 | $ 765,000 | $ 859,000 | |
Operating Lease, Payments | 225,000 | |||
Operating Lease, Cost | $ 135,000 | $ 343,000 | ||
Accounting Standards Update 2016-02 [Member] | ||||
Operating Lease, Right-of-Use Asset | $ 966,000 |
Note 5 - Leases - Lease Informa
Note 5 - Leases - Lease Information (Details) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Right-of-use operating lease assets, net | $ 765,000 | $ 859,000 |
Non-current lease liability | $ 648,000 | $ 761,000 |
Weighted average remaining lease term (Year) | 3 years 255 days | |
Discount rate | 22.00% | |
Current Liabilities [Member] | ||
Current lease liability | $ 147,000 |
Note 5 - Leases - Maturities of
Note 5 - Leases - Maturities of Lease Liabilities (Details) | Sep. 30, 2020USD ($) |
2020 (remaining) | $ 76,000 |
2021 | 310,000 |
2022 | 319,000 |
2023 | 328,000 |
2024 | 139,000 |
Thereafter | |
Total lease payments | 1,172,000 |
Less: imputed interest | (377,000) |
Present value of operating lease liabilities | $ 795,000 |
Note 6 - Commitments and Cont_3
Note 6 - Commitments and Contingencies (Details Textual) - USD ($) | May 01, 2020 | May 04, 2017 | Feb. 29, 2020 | Oct. 31, 2017 | Sep. 30, 2020 | Jul. 13, 2020 | Mar. 17, 2020 | Dec. 31, 2019 |
Short Term Investment Minimum | $ 1,000,000 | $ 1,000,000 | $ 2,000,000 | |||||
Litigation Related to Strategic Advisory Services [Member] | ||||||||
Loss Contingency, Damages Sought, Value | $ 1,000,000 | |||||||
Loss Contingency, Negotiation Condition Bond | $ 1,000,000 | |||||||
Loss Contingency, Damages Awarded, Value | $ 1,000,000 | |||||||
Gain (Loss) Related to Litigation Settlement, Total | (1,400,000) | |||||||
Litigation Settlement, Expense | 1,000,000 | |||||||
Litigation Settlement Interest | $ 400,000 | |||||||
Agreement with Plaintiff For Reimbursement of Trial Related Expenses [Member] | ||||||||
Litigation Settlement, Expense | $ 111,000 | |||||||
Litigation Settlement Interest | 369,000 | |||||||
Loss Contingency, Damages Awarded, Value | $ 480,000 | |||||||
Minimum [Member] | ||||||||
Period Of Warranty On Products (Year) | 1 year | |||||||
Maximum [Member] | ||||||||
Period Of Warranty On Products (Year) | 2 years |
Note 6 - Commitments and Cont_4
Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) | 9 Months Ended |
Sep. 30, 2020USD ($) | |
Balance | $ 277,000 |
Warranties issued during the period | 62,000 |
Settlements made during the period | (171,000) |
Changes in liability for pre-existing warranties during the period | (20,000) |
Balance | $ 148,000 |
Note 7 - Stockholders' Equity_2
Note 7 - Stockholders' Equity (Details Textual) - USD ($) | Mar. 27, 2020 | Dec. 13, 2019 | Nov. 12, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | May 19, 2020 |
Proceeds from Issuance of Common Stock, Net | $ 5,580,000 | $ 756,000 | ||||||
Share-based Payment Arrangement, Expense | $ 234,000 | $ 253,000 | $ 615,000 | $ 459,000 | ||||
Registered Direct Offering [Member] | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,000,002 | |||||||
Shares Issued, Price Per Share (in dollars per share) | $ 3.50 | |||||||
Proceeds from Issuance of Common Stock | $ 3,500,000 | |||||||
Payments of Stock Issuance Costs | $ 393,000 | |||||||
At The Market Offering Agreement [Member] | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 517,740 | |||||||
Proceeds from Issuance of Common Stock | $ 2,785,000 | |||||||
Payments of Stock Issuance Costs | $ 312,000 | |||||||
Maximum Offering Price for Issuance of Common Stock | $ 4,400,000 | $ 15,280,313 | ||||||
Commission as Percentage of Gross Proceeds | 3.00% | |||||||
Shares Issued, Average Price Per Share (in dollars per share) | $ 5.38 | |||||||
Proceeds from Issuance of Common Stock, Net | $ 2,473,000 | |||||||
At The Market Offering Agreement [Member] | Subsequent Event [Member] | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 964,130 | |||||||
Proceeds from Issuance of Common Stock | $ 2,771,000 | |||||||
Payments of Stock Issuance Costs | $ 88,000 | |||||||
Shares Issued, Average Price Per Share (in dollars per share) | $ 2.87 | |||||||
Proceeds from Issuance of Common Stock, Net | $ 2,683,000 |
Note 7 - Stockholders' Equity -
Note 7 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Stock-based compensation | $ 234,000 | $ 253,000 | $ 615,000 | $ 459,000 |
Cost of Sales [Member] | ||||
Stock-based compensation | 3,000 | 1,000 | 5,000 | 2,000 |
Selling and Marketing Expense [Member] | ||||
Stock-based compensation | 65,000 | 110,000 | 106,000 | 166,000 |
Research and Development Expense [Member] | ||||
Stock-based compensation | 36,000 | 38,000 | 72,000 | 75,000 |
General and Administrative Expense [Member] | ||||
Stock-based compensation | $ 130,000 | $ 104,000 | $ 432,000 | $ 216,000 |
Note 7 - Stockholders' Equity_3
Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) | 9 Months Ended |
Sep. 30, 2020USD ($)$ / sharesshares | |
Outstanding, options (in shares) | shares | 291,807 |
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares | $ 13.96 |
Granted, options (in shares) | shares | 615,500 |
Granted, weighted average exercise price, options (in dollars per share) | $ / shares | $ 5.92 |
Forfeited, options (in shares) | shares | (15,158) |
Forfeited, weighted average exercise price, options (in dollars per share) | $ / shares | $ 5.13 |
Outstanding, options (in shares) | shares | 892,149 |
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares | $ 8.57 |
Outstanding, weighted average remaining contractual life, options (Year) | 8 years 363 days |
Outstanding, aggregate intrinsic value, options | $ | |
Vested and expected to vest, options (in shares) | shares | 565,836 |
Vested and expected to vest, weighted average exercise price, options (in dollars per share) | $ / shares | $ 9.91 |
Vested and expected to vest, weighted average remaining contractual life, options (Year) | 8 years 268 days |
Vested and expected to vest, aggregate intrinsic value, options | $ | |
Exercisable, options (in shares) | shares | 184,137 |
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares | $ 17.05 |
Exercisable, weighted average remaining contractual life, options (Year) | 7 years 242 days |
Exercisable, aggregate intrinsic value, options | $ |
Note 7 - Stockholders' Equity_4
Note 7 - Stockholders' Equity - Warrant Activity (Details) | 9 Months Ended |
Sep. 30, 2020$ / sharesshares | |
Outstanding (in shares) | shares | 1,716,066 |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 25.23 |
Warrants expired (in shares) | shares | |
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares | |
Warrants exercised (in shares) | shares | (599,582) |
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 2.81 |
Outstanding (in shares) | shares | 1,116,484 |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 37.27 |
Exercisable (in shares) | shares | 1,046,631 |
Exercisable, weighted average exercise price (in dollars per share) | $ / shares | $ 34.42 |
Note 8 - Major Customers and _2
Note 8 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member] | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | |
Revenue Benchmark [Member] | Customer 1 [Member] | |||||
Concentration Risk, Percentage | 22.00% | 27.00% | 28.00% | 29.00% | |
Revenue Benchmark [Member] | Customer 2 [Member] | |||||
Concentration Risk, Percentage | 20.00% | 13.00% | 12.00% | 13.00% | |
Revenue Benchmark [Member] | Customer 3 [Member] | |||||
Concentration Risk, Percentage | 10.00% | 2.00% | 12.00% | 0.00% | |
Accounts Receivable [Member] | Two Customers [Member] | |||||
Concentration Risk, Percentage | 59.00% | 53.00% |